TScan Therapeutics administered the first dose of its lead T-cell therapy candidate, TSC-101, in the pivotal Phase 3 ALLOHA-2™ clinical trial.
The study enrolls patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who have received a specific stem cell transplant. Researchers are evaluating the therapy's ability to prevent cancer relapse in this population.
Relapse-free survival serves as the primary endpoint for the late-stage study. Positive safety and efficacy data from previous trials supported the advancement to Phase 3.
TScan is currently enrolling participants at sites across the United States. The company expects to announce topline data from the trial in mid-2028.